SELLAS Life Sciences Appoints New CMO, Dr. Stergiou
Ticker: SLS · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel, compensation
TL;DR
New CMO in, old CMO out at SELLAS. Stergiou takes over with $450K salary + stock options.
AI Summary
On March 6, 2024, SELLAS Life Sciences Group, Inc. announced the appointment of Dr. Angelos Stergiou as Chief Medical Officer and the resignation of Dr. John "Jack" B. Greene from the same role. Dr. Stergiou's compensation includes an annual base salary of $450,000, a target bonus of 40% of his base salary, and stock options.
Why It Matters
The change in Chief Medical Officer could signal a shift in the company's clinical development strategy or focus for its drug candidates.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate strategic shifts or challenges within a life sciences company.
Key Numbers
- $450,000 — Annual Base Salary (For new Chief Medical Officer, Dr. Angelos Stergiou)
- 40% — Target Bonus (For new Chief Medical Officer, Dr. Angelos Stergiou)
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- Dr. Angelos Stergiou (person) — Appointed Chief Medical Officer
- Dr. John "Jack" B. Greene (person) — Resigned Chief Medical Officer
- $450,000 (dollar_amount) — Dr. Stergiou's annual base salary
FAQ
What is Dr. Stergiou's prior experience relevant to SELLAS' pipeline?
The filing does not detail Dr. Stergiou's specific prior experience, but his appointment as CMO suggests relevant expertise in clinical development.
What is the effective date of Dr. Stergiou's appointment and Dr. Greene's resignation?
The earliest event reported is March 6, 2024, indicating these changes occurred on or before this date.
Are there any severance details for Dr. Greene?
The provided text does not include information regarding severance packages for Dr. Greene.
What are the terms of the stock options granted to Dr. Stergiou?
The filing mentions stock options as part of Dr. Stergiou's compensation, but specific terms such as vesting schedules or exercise prices are not detailed in this excerpt.
What is SELLAS Life Sciences Group's primary focus area?
SELLAS Life Sciences Group, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-08 16:05:42
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm248331d1_8k.htm (8-K) — 29KB
- tm248331d1_ex99-1.htm (EX-99.1) — 10KB
- tm248331d1_ex99-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-032384.txt ( ) — 227KB
- sls-20240306.xsd (EX-101.SCH) — 3KB
- sls-20240306_lab.xml (EX-101.LAB) — 33KB
- sls-20240306_pre.xml (EX-101.PRE) — 22KB
- tm248331d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 8, 2024, the Company issued a press release (the "Press Release") announcing executive leadership reorganization and prioritization of commercialization partnerships. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. 2
01. Financial
Item 9.01. Financial (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: March 8, 2024 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer 4